Q1 2025 Progyny Inc Earnings Call Transcript
Key Points
- Progyny Inc (PGNY) reported double-digit growth in both revenue and adjusted EBITDA, achieving record quarterly results.
- The company raised its full-year guidance, reflecting strong performance and consistent member engagement.
- Progyny Inc (PGNY) expanded its product portfolio and platform, enhancing its member experience and solidifying its position in women's health and family building.
- The company saw a 19% increase in first-quarter revenue, excluding the impact of a large transitioning client, highlighting strong core business growth.
- Progyny Inc (PGNY) generated nearly USD 50 million in operating cash flow in the first quarter, nearly doubling the prior year period.
- The average number of lives in the sales pipeline is lower compared to the previous year, potentially impacting future growth.
- Adjusted EBITDA margin declined modestly due to incremental investments in platform and product expansion.
- The company anticipates variability in member engagement and treatment activity, reflecting uncertainty in the macro environment.
- Progyny Inc (PGNY) expects gross margin expansion to be lower for the full year compared to Q1 due to additional hiring and investments.
- The company faces potential risks from tariffs on pharmaceuticals, which could impact costs, although current tariffs have not yet affected them.
Good day ladies and gentlemen, and welcome to the Progeny Inc. first quarter 2025 earnings conference call. [Operator Instructions].
It is now my pleasure to turn the floor over to your host James Hart. James, the floor is yours.
Thank you, Tom, and good afternoon everyone. Welcome to our first quarter conference call. With me today are Peter Anevski; CEO of Progeny, Michael Sturmer; President, and Mark Livingston; CFO. We will begin with some prepared remarks before we open the call for your questions.
Before we begin, I'd like to remind you that our comments and responses to your questions today reflect management's views as of today only, and we'll include statements related to our financial outlook for both the second quarter and full year 2025.
Any assumptions and drivers underlying such guidance, our anticipated number of clients and covered lives for 2025, the demand for our solutions, our expectations for our selling season for 2026 launches, anticipated employment levels of our
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
